Management of stage I testicular germ cell tumours

Michal Chovanec, Nasser Hanna, K. Clinton Cary, Lawrence Einhorn, Costantine Albany

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Clinical stage I testicular germ cell tumours (TGCT) are highly curable neoplasms. The treatment of stage I testicular cancer is complex and requires a multidisciplinary approach. Standard options after radical orchiectomy for seminoma include active surveillance, radiation therapy or 1-2 cycles of carboplatin, and options for nonseminoma include active surveillance, retroperitoneal lymph node dissection (RPLND) or 1-2 cycles of bleomycin plus etoposide plus cisplatin (BEP). All the options should be discussed with each patient and treatment choices should be made by shared decision making as virtually all patients with clinical stage I TGCT can be cured of their disease. Long-term survival of men with stage I disease is â 1/499% and care must be taken to limit the long-term risks of treatment. Orchiectomy is curative in the majority of patients. The management of clinical stage I TGCT remains controversial among experts at high-volume centres throughout the world. The main controversy is whether to overtreat a substantial number of patients with stage I disease to prevent relapse, or to observe and treat only patients who experience disease relapse as adjuvant treatment and surveillance strategy both bring curative outcome. Thus, a summary of the available evidence in stage I disease and recommendations for disease management from a high-volume centre such as Indiana University might be of interest to treating clinicians.

Original languageEnglish (US)
Pages (from-to)663-673
Number of pages11
JournalNature Reviews Urology
Volume13
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Orchiectomy
Recurrence
Seminoma
Carboplatin
Bleomycin
Testicular Neoplasms
Etoposide
Therapeutics
Disease Management
Lymph Node Excision
Cisplatin
Decision Making
Radiotherapy
Testicular Germ Cell Tumor
Survival
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Management of stage I testicular germ cell tumours. / Chovanec, Michal; Hanna, Nasser; Cary, K. Clinton; Einhorn, Lawrence; Albany, Costantine.

In: Nature Reviews Urology, Vol. 13, No. 11, 01.11.2016, p. 663-673.

Research output: Contribution to journalReview article

Chovanec, Michal ; Hanna, Nasser ; Cary, K. Clinton ; Einhorn, Lawrence ; Albany, Costantine. / Management of stage I testicular germ cell tumours. In: Nature Reviews Urology. 2016 ; Vol. 13, No. 11. pp. 663-673.
@article{5125208b561040a5984bc0e1c13fcd83,
title = "Management of stage I testicular germ cell tumours",
abstract = "Clinical stage I testicular germ cell tumours (TGCT) are highly curable neoplasms. The treatment of stage I testicular cancer is complex and requires a multidisciplinary approach. Standard options after radical orchiectomy for seminoma include active surveillance, radiation therapy or 1-2 cycles of carboplatin, and options for nonseminoma include active surveillance, retroperitoneal lymph node dissection (RPLND) or 1-2 cycles of bleomycin plus etoposide plus cisplatin (BEP). All the options should be discussed with each patient and treatment choices should be made by shared decision making as virtually all patients with clinical stage I TGCT can be cured of their disease. Long-term survival of men with stage I disease is {\^a} 1/499{\%} and care must be taken to limit the long-term risks of treatment. Orchiectomy is curative in the majority of patients. The management of clinical stage I TGCT remains controversial among experts at high-volume centres throughout the world. The main controversy is whether to overtreat a substantial number of patients with stage I disease to prevent relapse, or to observe and treat only patients who experience disease relapse as adjuvant treatment and surveillance strategy both bring curative outcome. Thus, a summary of the available evidence in stage I disease and recommendations for disease management from a high-volume centre such as Indiana University might be of interest to treating clinicians.",
author = "Michal Chovanec and Nasser Hanna and Cary, {K. Clinton} and Lawrence Einhorn and Costantine Albany",
year = "2016",
month = "11",
day = "1",
doi = "10.1038/nrurol.2016.164",
language = "English (US)",
volume = "13",
pages = "663--673",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Management of stage I testicular germ cell tumours

AU - Chovanec, Michal

AU - Hanna, Nasser

AU - Cary, K. Clinton

AU - Einhorn, Lawrence

AU - Albany, Costantine

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Clinical stage I testicular germ cell tumours (TGCT) are highly curable neoplasms. The treatment of stage I testicular cancer is complex and requires a multidisciplinary approach. Standard options after radical orchiectomy for seminoma include active surveillance, radiation therapy or 1-2 cycles of carboplatin, and options for nonseminoma include active surveillance, retroperitoneal lymph node dissection (RPLND) or 1-2 cycles of bleomycin plus etoposide plus cisplatin (BEP). All the options should be discussed with each patient and treatment choices should be made by shared decision making as virtually all patients with clinical stage I TGCT can be cured of their disease. Long-term survival of men with stage I disease is â 1/499% and care must be taken to limit the long-term risks of treatment. Orchiectomy is curative in the majority of patients. The management of clinical stage I TGCT remains controversial among experts at high-volume centres throughout the world. The main controversy is whether to overtreat a substantial number of patients with stage I disease to prevent relapse, or to observe and treat only patients who experience disease relapse as adjuvant treatment and surveillance strategy both bring curative outcome. Thus, a summary of the available evidence in stage I disease and recommendations for disease management from a high-volume centre such as Indiana University might be of interest to treating clinicians.

AB - Clinical stage I testicular germ cell tumours (TGCT) are highly curable neoplasms. The treatment of stage I testicular cancer is complex and requires a multidisciplinary approach. Standard options after radical orchiectomy for seminoma include active surveillance, radiation therapy or 1-2 cycles of carboplatin, and options for nonseminoma include active surveillance, retroperitoneal lymph node dissection (RPLND) or 1-2 cycles of bleomycin plus etoposide plus cisplatin (BEP). All the options should be discussed with each patient and treatment choices should be made by shared decision making as virtually all patients with clinical stage I TGCT can be cured of their disease. Long-term survival of men with stage I disease is â 1/499% and care must be taken to limit the long-term risks of treatment. Orchiectomy is curative in the majority of patients. The management of clinical stage I TGCT remains controversial among experts at high-volume centres throughout the world. The main controversy is whether to overtreat a substantial number of patients with stage I disease to prevent relapse, or to observe and treat only patients who experience disease relapse as adjuvant treatment and surveillance strategy both bring curative outcome. Thus, a summary of the available evidence in stage I disease and recommendations for disease management from a high-volume centre such as Indiana University might be of interest to treating clinicians.

UR - http://www.scopus.com/inward/record.url?scp=84987625599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987625599&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2016.164

DO - 10.1038/nrurol.2016.164

M3 - Review article

C2 - 27618772

AN - SCOPUS:84987625599

VL - 13

SP - 663

EP - 673

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 11

ER -